



Otrodo	140			Odda Datia (050( Od)		
Study	I^2	1		Odds Ratio (95% Crl)		
Afatinib_Cetuximab vs Afatinib						
29			<del></del>	3.1 (0.50, 20.)		
Pooled (pair-wise)		-	-	3.0 (0.50, 27.)		
Indirect (back-calculated)				NA		
Pooled (network)		-	<del></del>	3.0 (0.51, 27.)		
Chemotherapy vs Afatini	ib					
50		<del></del>		1.3 (0.34, 5.2)		
57		<del></del>	$\longrightarrow$	6.1e+10 (4.1e-06, 9.2e+26)		
Pooled (pair-wise)	46.6%		•	1.9 (0.42, 9.0)		
Indirect (back-calculated)				0.90 (0.38, 2.2)		
Pooled (network)	0.0%	-		1.1 (0.51, 2.3)		
<b>Erlotinib vs Afatinib</b>						
38			_	0.99 (0.48, 2.0)		
Pooled (pair-wise)				1.0 (0.33, 3.0)		
Indirect (back-calculated)		⊙		0.72 (0.30, 1.7)		
Pooled (network)	0.0%		-	0.82 (0.42, 1.7)		
Gefitinib vs Afatinib						
48		<del></del>		0.50 (0.19, 1.3)		
Pooled (pair-wise)		-	_	0.51 (0.14, 1.8)		
Indirect (back-calculated)				0.68 (0.23, 2.1)		
Pooled (network)	0.0%			0.60 (0.26, 1.4)		
Placebo vs Afatinib						
54		<del></del>		0.24 (0.044, 1.3)		
Pooled (pair-wise)		-		0.24 (0.030, 1.3)		
Indirect (back-calculated)				0.75 (0.33, 1.7)		
Pooled (network)	30.5%	_=		0.62 (0.29, 1.3)		
,		0.02	200	,		
		0.03 1	30			




Study	I^2		Odds Ratio (95% Crl)
Gefitinib vs Chemothera	ру		
73 75 76 77 Pooled (pair–wise) Indirect (back–calculated)	49.1%		→ 8.0e-18 (4.3e-43, 1.5e+08)
Pooled (network)	29.5%		0.56 (0.24, 1.2)
Osimertinib vs Chemoth	erapy		
42 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%		0.70 (0.25, 2.0) 0.68 (0.19, 2.7) 1.1 (0.34, 3.8) 0.90 (0.38, 2.3)
<b>Erlotinib vs Dacomitinib</b>			,
45 59 Pooled (pair–wise) Indirect (back–calculated)	15.1%		> 6.5 (0.43, 1.e+02) 1.4 (0.55, 3.3) 1.7 (0.64, 5.5) 0.82 (0.26, 2.6)
Pooled (network)	0.0%	<del>- -</del>	1.2 (0.57, 2.7)
Gefitinib vs Dacomitinib			
43 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%	0.03	0.37 (0.019, 7.3) 0.40 (0.012, 5.5) 0.98 (0.33, 2.9) 0.88 (0.32, 2.5)









Study	I^2			Odds Ratio (95% Crl)
antiangio vs Erlotinib				
28 37		<del></del>	<del></del>	1.3 (0.67, 2.7) 2.8e+07 (2.6e-06, 2.9e+20)
Pooled (pair–wise) Indirect (back–calculated)	17.6%		-	1.4 (0.47, 4.2) NA
Pooled (network)	52.0%		<del>  -</del>	1.9 (0.87, 4.9)
Osimertinib vs Gefitinib_	_Erlotinib			
31 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)			•	2.9 (0.97, 8.4) 2.8 (0.77, 12.) NA 2.9 (0.83, 10.)
Gefitinib_chemotherapy	vs Gefitinib			
14 23 49		<del>-</del>	→ → → →	1.7 (0.23, 13.) 1.2e+12 (6.1e-08, 2.3e+31) 8.4 (0.60, 1.2e+02)
Pooled (pair–wise) Indirect (back–calculated)			-	3.5 (0.89, 18.) NA
Pooled (network)	12.5%		-	3.7 (0.94, 18.)
Lazertinib vs Gefitinib				
r17 Pooled (pair–wise)			• • • • • • • • • • • • • • • • • • •	2.8 (0.81, 9.7) 2.7 (0.68, 13.)
Indirect (back-calculated) Pooled (network)	0.0%	0.03	1 30	2.1 (0.54, 8.3) 2.3 (0.86, 6.5)

